CD155 and its receptors in cancer immune escape and immunotherapy

Ruijia Zhou; Shiyin Chen; Qiwen Wu; Lingyun Liu; Yian Wang; Yongzhen Mo; Zhaoyang Zeng; Xuyu Zu; Wei Xiong; Fuyan Wang

doi:10.1016/j.canlet.2023.216381

CD155 and its receptors in cancer immune escape and immunotherapy

Cancer Lett. 2023 Oct 1:573:216381. doi: 10.1016/j.canlet.2023.216381. Epub 2023 Sep 3.

Authors

Ruijia Zhou¹, Shiyin Chen¹, Qiwen Wu¹, Lingyun Liu², Yian Wang¹, Yongzhen Mo¹, Zhaoyang Zeng¹, Xuyu Zu², Wei Xiong³, Fuyan Wang⁴

Affiliations

¹ NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China; Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China; Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
² Cancer Research Institute, The First Affiliated Hospital, Hengyang Medical College, University of South China, Hengyang, 421001, China.
³ NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China; Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China; Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China. Electronic address: xiongwei@csu.edu.cn.
⁴ NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China; Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China; Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China. Electronic address: wfy4010@csu.edu.cn.

PMID: 37660884
DOI: 10.1016/j.canlet.2023.216381

Abstract

In recent years, there have been multiple breakthroughs in cancer immunotherapy, with immune checkpoint inhibitors becoming the most promising treatment strategy. However, available drugs are not always effective. As an emerging immune checkpoint molecule, CD155 has become an important target for immunotherapy. This review describes the structure and function of CD155, its receptors TIGIT, CD96, and CD226, and summarizes that CD155 expressed by tumor cells can upregulate its expression through the DNA damage response pathway and Ras-Raf-MEK-ERK signaling pathway. This review also elaborates the mechanism of immune escape after binding CD155 to its receptors TIGIT, CD96, and CD226, and summarizes the current progress of immunotherapy research regarding CD155 and its receptors. Besides, it also discusses the future direction of checkpoint immunotherapy.

Keywords: CD155; CD96; Cancer immunotherapy; TIGIT; immune escape.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antigens, CD
Humans
Immune Checkpoint Inhibitors
Immunotherapy*
MAP Kinase Signaling System
Neoplasms* / therapy

Substances

Immune Checkpoint Inhibitors
Antigens, CD